WO2023107058A2 - Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit - Google Patents

Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit Download PDF

Info

Publication number
WO2023107058A2
WO2023107058A2 PCT/TR2022/051394 TR2022051394W WO2023107058A2 WO 2023107058 A2 WO2023107058 A2 WO 2023107058A2 TR 2022051394 W TR2022051394 W TR 2022051394W WO 2023107058 A2 WO2023107058 A2 WO 2023107058A2
Authority
WO
WIPO (PCT)
Prior art keywords
carbapenemase
oxa
pcr
oxacillinase
diagnostic kit
Prior art date
Application number
PCT/TR2022/051394
Other languages
French (fr)
Other versions
WO2023107058A3 (en
Inventor
Şebnem BUKAVAZ
Original Assignee
Trakya Üni̇versi̇tesi̇ Rektörlüğü
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trakya Üni̇versi̇tesi̇ Rektörlüğü filed Critical Trakya Üni̇versi̇tesi̇ Rektörlüğü
Priority to EP22904821.0A priority Critical patent/EP4413152A2/en
Publication of WO2023107058A2 publication Critical patent/WO2023107058A2/en
Publication of WO2023107058A3 publication Critical patent/WO2023107058A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Definitions

  • the present invention relates to a PCR-based rapid diagnostic kit for the detection of carbapenemases causing antibiotic (carbapenem) resistance.
  • Carbapenemases are P-lactamases that hydrolyze penicillin, that hydrolyze cephalosporins in most cases and hydrolyze carbapenems and monobactams to a certain extent.
  • carbapenemases in the Enterobacteriaceae family worldwide are Klebsiella pneumoniae, Acinetobacter baumannii carbapenemase (KPC), New Delhi metallo-P- lactamase (NDM), and oxacillinase-48 OXA-48; E. coli carbapenemases KPC, OXA, NDM, VIM and IMP; Enterococcus spp. common Vancomycin resistance genes Van A, VanB, and Staphylococcus aureus Methicillin resistance gene MecA enzymes.
  • the carbapenems are the antibiotics with the broadest spectrum in the beta-lactam class with rapid bactericidal action and are widely used in infections caused by many aerobic and anaerobic microorganisms with their broad antibacterial spectrum.
  • Carbapenemases are identified in routine microbiology laboratories by traditional culture and antibiogram determination.
  • the bacteria are first cultured from the patient and after 24 hours of incubation, the bacteria are named using automated systems.
  • the working principle of the systems is based on the metabolites used by the bacteria during reproduction and the resulting enzymes and pH changes are basically named based on their biochemical properties.
  • the antibiogram uses automated systems to determine which antibiotic the said bacteria is susceptible to.
  • the said procedure while the presence of the resistance enzyme is indicated, no definitive judgment can be made about the details and type of resistance.
  • it is not possible to prevent infectiousness and thus outbreaks by identifying the type of plasmid-mediated enzyme that is dangerous and spreads rapidly among patients and isolating a patient from other patients.
  • Phenotypic Carba NP and the Modified Hodge Test are also used for the identification of carbapenemases in the known state of the art. Although MHT is highly susceptible in Klebsiella pneumoniae, it does not perform well in other Enterobacteriaceae members. Furthermore, in the state of the art, these tests confirm the presence of a general carbapenemase but cannot identify the precise name of the enzyme causing resistance. Although the Carba NP test is reliable, it is not preferred due to its excessive cost.
  • the present invention aims to design a PCR-based rapid diagnostic kit for the detection of antibiotic-resistant carbapenemases.
  • the PCR-based rapid diagnostic kit of the invention enables rapid (2-3 hours) identification of enzymes that cause resistance to antibiotics and detects which enzyme causes resistance.
  • a plasmid-mediated enzyme the patient is rapidly isolated, and the spread of resistance is prevented.
  • kits to be used for diagnostic purposes in microbiology routine laboratories can be produced based on probe hybridization technique, while those to be used in screening tests and epidemiological research studies can be produced with Conventional Single or Multiplex Sybr- Green, Probe-Hybridization techniques.
  • the kit of the invention enables rapid diagnosis (2-3 hours) of important (Kpc-2, Oxa-48-23-24- 58, Ndm-1, IMP, VIM, VanA, VanB, mecA, mcr-1, BIC) resistance genes, which are frequently encountered in our country and which pose a danger since their spread is plasmid-mediated, and has a very low cost.
  • Bacteria reference strains such as carbapenemase-positive Escherichia coli, Klebsiella pneumoniae, Acinetobacter spp., Pseudomonas aeruginosa, Enterococcus faecalis, Enterococcus f aecium, Staphylococcus aureus, etc.
  • the PCR-based diagnostic kit of the invention for the detection of antibiotic-resistant carbapenemases comprises; DNA primer pairs NO: 1, NO:2 and NO:3, NO:4, NO:5, NO:6, NO:7, NO:8, NO:9, NO:10, NO: 11, NO:12, NO:13, NO:14, NO: 15, NO: 16, NO: 17, NO: 18, NO: 19, NO:20, NO:21, NO:22, NO:23, NO:24, NO:25, NO:26, NO:27, NO:28, NO:29, NO:30 to detect enzyme types from the carbapenemase group, including Klebsiella pneumoniae carbapenemase (KPC) belonging to the carbapenemase group, New Delhi metallo-P-lactamase (NDM), oxacillinase-48 (Oxa-48), Colistin Resistance (MCR), Oxacillinase-23 (Oxa-23), Oxacillinase-24 (Oxa- 24), Oxacillinas
  • the invention is firstly produced by accumulating bacteria (1) such as Carbapenemase-positive Escherichia coli, Klebsiella pneumoniae, Acinetobacter spp., Pseudomonas aeruginosa, Enterococcus fecalis, E. Faecium and Staphylococcus aures etc. at -80 °C.
  • bacteria (1) such as Carbapenemase-positive Escherichia coli, Klebsiella pneumoniae, Acinetobacter spp., Pseudomonas aeruginosa, Enterococcus fecalis, E. Faecium and Staphylococcus aures etc. at -80 °C.
  • clinical samples (2) are prepared in routine diagnostic laboratories as recommended in the selected DNA isolation kit and bacterial culture (3) is produced from clinical samples such as blood, endotracheal aspirate, urine, and sputum sent to the laboratory.
  • Direct DNA isolation from clinical samples (4) and DNA isolation from bacterial culture (5) are performed simultaneously with a DNA isolation kit or boiling method. If the PCR step is not to be performed immediately, the samples are stored at +4°C for a short time (a few weeks) and at -80°C for a period of 6 months.
  • kits that enable the detection of the appropriate number of enzymes for the study objects can be produced by Conventional Single (7) or Multiplex (8) and Multiplex Sybr-Green (9), Probe-Hybridization (10) and measurements can be performed.
  • multiplex PCR can be performed with any two or three of the blaKPC-2, blaOXA-48, blaXDM , blaOXA-23, blaOXA-24, blaOXA-58, blaOXA-204, blaOXA- 181, /W/VIM, blaAMP, blaBIC, mecA, vanA, vanB blaMCR-1 gene regions or in a single reaction depending on the number of PCR device channels, and probe hybridization can be performed with single and/or multiple enzymes.
  • PCR kits are produced that enable the amplification of the selected DNA regions ready to be designed in different types suitable for the objects of the study.
  • Table 1 shows the DNA primer pairs included in the kit that are specific for the detection of different carbapenemase genes.
  • Table 1 DNA primer pairs included in the kit that are specific for the detection of different carbapenemase genes
  • kits contains a solution and materials called master mix, which includes Taq DNA polymerase enzyme and primers specific to the region to be amplified, as well as tubes prepared as control.
  • master mix which includes Taq DNA polymerase enzyme and primers specific to the region to be amplified, as well as tubes prepared as control.
  • the reaction is completed in a short time (approximately 3-4 hours) in a thermal cycling device.
  • DNA sequence and variant analysis (10), PCR samples are run on a 1% agarose gel at 100V for 30 minutes if the traditional PCR kit is selected. If a Real-Time PCR kit is selected, Melt-Curve analysis and accurate melting points as well as internal amplification controls (IAK) are evaluated, and results are recorded.
  • the enzyme variation will also be statistically evaluated by examining the nucleotide differences according to the DNA Sequence Analysis result of the selected samples.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a PCR-based rapid diagnostic kit for the detection of carbapenemases.

Description

DIRECT CARBAPENEMASE TRIPLE (KPC-2, OXA-48, NDM-1) PCR DIAGNOSTIC
KIT
Technical Field of Invention
The present invention relates to a PCR-based rapid diagnostic kit for the detection of carbapenemases causing antibiotic (carbapenem) resistance.
State of the Art Related to the Invention (Background)
Carbapenemases are P-lactamases that hydrolyze penicillin, that hydrolyze cephalosporins in most cases and hydrolyze carbapenems and monobactams to a certain extent.
Infections caused by extended-spectrum beta-lactamases (ESBLs) and carbapenemase-producing Gram-negative bacteria in recent years have posed serious therapeutic problems, especially in hospitalized patients and those with underlying immunosuppressive conditions.
The most commonly detected carbapenemases in the Enterobacteriaceae family worldwide are Klebsiella pneumoniae, Acinetobacter baumannii carbapenemase (KPC), New Delhi metallo-P- lactamase (NDM), and oxacillinase-48 OXA-48; E. coli carbapenemases KPC, OXA, NDM, VIM and IMP; Enterococcus spp. common Vancomycin resistance genes Van A, VanB, and Staphylococcus aureus Methicillin resistance gene MecA enzymes.
The carbapenems are the antibiotics with the broadest spectrum in the beta-lactam class with rapid bactericidal action and are widely used in infections caused by many aerobic and anaerobic microorganisms with their broad antibacterial spectrum.
In the state of the art; Carbapenemases are identified in routine microbiology laboratories by traditional culture and antibiogram determination. Using the traditional method of bacterial identification and antibiogram used in routine microbiology laboratories, the bacteria are first cultured from the patient and after 24 hours of incubation, the bacteria are named using automated systems. The working principle of the systems is based on the metabolites used by the bacteria during reproduction and the resulting enzymes and pH changes are basically named based on their biochemical properties. Although there is no technical problem in the use of these methods for the said Enterobacteriaceae member bacteria, at least 48 hours are needed for detection and during this time, resistance enzymes spread rapidly from one patient to another.
As a secondary procedure, the antibiogram uses automated systems to determine which antibiotic the said bacteria is susceptible to. During the said procedure, while the presence of the resistance enzyme is indicated, no definitive judgment can be made about the details and type of resistance. Thus, it is not possible to prevent infectiousness and thus outbreaks by identifying the type of plasmid-mediated enzyme that is dangerous and spreads rapidly among patients and isolating a patient from other patients.
Phenotypic Carba NP and the Modified Hodge Test (MHT) are also used for the identification of carbapenemases in the known state of the art. Although MHT is highly susceptible in Klebsiella pneumoniae, it does not perform well in other Enterobacteriaceae members. Furthermore, in the state of the art, these tests confirm the presence of a general carbapenemase but cannot identify the precise name of the enzyme causing resistance. Although the Carba NP test is reliable, it is not preferred due to its excessive cost.
Usually, conventional PCR or internationally produced kits are used for the determination of enzymes in our country. The cost of these kits is quite high as they contain many enzymes other than the important (Kpc-2, Oxa-48, Ndm-1, IMP, VIM, VanA, VanB, mecA, mcr-1, BIC) enzymes that are frequently seen in our country and cause problems and are produced abroad. The determination of resistance also takes a longer time. The patent numbered US 9,914,980 B2 relates to a kit for the identification of carbapenemase genes, which determines more than 170 carbapenemase enzyme types. Therefore, resistance determination takes a considerably long time.
Brief Description and Objects of the Invention
The present invention aims to design a PCR-based rapid diagnostic kit for the detection of antibiotic-resistant carbapenemases.
The PCR-based rapid diagnostic kit of the invention enables rapid (2-3 hours) identification of enzymes that cause resistance to antibiotics and detects which enzyme causes resistance. In the case of a plasmid-mediated enzyme, the patient is rapidly isolated, and the spread of resistance is prevented.
The rapid spread of resistance enzymes from one patient to another, which is important for patients with high comorbidity hospitalized in intensive care units, is prevented and the patient is isolated from other patients, and infectiousness is prevented.
The contents of the kit of the invention can be simply designed to correspond to the intended use. For example, kits to be used for diagnostic purposes in microbiology routine laboratories can be produced based on probe hybridization technique, while those to be used in screening tests and epidemiological research studies can be produced with Conventional Single or Multiplex Sybr- Green, Probe-Hybridization techniques.
The kit of the invention enables rapid diagnosis (2-3 hours) of important (Kpc-2, Oxa-48-23-24- 58, Ndm-1, IMP, VIM, VanA, VanB, mecA, mcr-1, BIC) resistance genes, which are frequently encountered in our country and which pose a danger since their spread is plasmid-mediated, and has a very low cost.
Descriptions of the Figures Illustrating the Invention Figure 1: Workflow diagram
Descriptions of the elements/sections/parts that constitute the invention
1. Bacteria reference strains such as carbapenemase-positive Escherichia coli, Klebsiella pneumoniae, Acinetobacter spp., Pseudomonas aeruginosa, Enterococcus faecalis, Enterococcus f aecium, Staphylococcus aureus, etc.
2. Clinical sample
3. Bacterial culture from a clinical sample
4. Direct DNA isolation from a clinical sample
5. DNA isolation from bacterial culture
6. Standardization of DNA isolation, determination of specificity and susceptibility
7. Conventional PCR (blaKPC-2, blaOXA-48, blaNDM-1, blaOXA-23, blaOXA-24, blaOXA-58, blaOXA-204, blaOXA- 181, blaVLM, blaIMP, blaBIC, mecA, vanA, vanB)
8. Multiplex PCR
9. Quantitative Sybr-Green Multiplex PCR
10. Quantitative Prob-Hibridizasyon
11. DNA sequence and variant analysis
Detailed Description of the Invention
The PCR-based diagnostic kit of the invention for the detection of antibiotic-resistant carbapenemases comprises; DNA primer pairs NO: 1, NO:2 and NO:3, NO:4, NO:5, NO:6, NO:7, NO:8, NO:9, NO:10, NO: 11, NO:12, NO:13, NO:14, NO: 15, NO: 16, NO: 17, NO: 18, NO: 19, NO:20, NO:21, NO:22, NO:23, NO:24, NO:25, NO:26, NO:27, NO:28, NO:29, NO:30 to detect enzyme types from the carbapenemase group, including Klebsiella pneumoniae carbapenemase (KPC) belonging to the carbapenemase group, New Delhi metallo-P-lactamase (NDM), oxacillinase-48 (Oxa-48), Colistin Resistance (MCR), Oxacillinase-23 (Oxa-23), Oxacillinase-24 (Oxa- 24), Oxacillinase-58 (Oxa-58), Pseudomonas aeruginosa carbapenemases (blaVIM, blaTMP, and blaBIC), enterococcal Vancomycin resistance genes (vanA, vanB), Staphylococcus aureus methicillin resistance gene (MecA). According to the process step sequence shown in Figure 1; the invention is firstly produced by accumulating bacteria (1) such as Carbapenemase-positive Escherichia coli, Klebsiella pneumoniae, Acinetobacter spp., Pseudomonas aeruginosa, Enterococcus fecalis, E. Faecium and Staphylococcus aures etc. at -80 °C. Afterward, clinical samples (2) are prepared in routine diagnostic laboratories as recommended in the selected DNA isolation kit and bacterial culture (3) is produced from clinical samples such as blood, endotracheal aspirate, urine, and sputum sent to the laboratory. Direct DNA isolation from clinical samples (4) and DNA isolation from bacterial culture (5) are performed simultaneously with a DNA isolation kit or boiling method. If the PCR step is not to be performed immediately, the samples are stored at +4°C for a short time (a few weeks) and at -80°C for a period of 6 months. After standardization of DNA isolation, determination of specificity and susceptibility (6), kits that enable the detection of the appropriate number of enzymes for the study objects can be produced by Conventional Single (7) or Multiplex (8) and Multiplex Sybr-Green (9), Probe-Hybridization (10) and measurements can be performed. While single conventional PCR can be performed with any of blaKPC-2, blaOXA-48, bla DM-1, blaOXA-23, blaOXA-24, blaOXA-58, blaOXA-204, blaOXA- 181, blaVLM, blaIMP, blaB C, mecA, vanA, vanB /Vc/MCR-k, multiplex PCR can be performed with any two or three of the blaKPC-2, blaOXA-48, blaXDM , blaOXA-23, blaOXA-24, blaOXA-58, blaOXA-204, blaOXA- 181, /W/VIM, blaAMP, blaBIC, mecA, vanA, vanB blaMCR-1 gene regions or in a single reaction depending on the number of PCR device channels, and probe hybridization can be performed with single and/or multiple enzymes. In this art, by using primers targeting the DNA regions encoding the problematic resistance enzymes, PCR kits are produced that enable the amplification of the selected DNA regions ready to be designed in different types suitable for the objects of the study. Table 1 shows the DNA primer pairs included in the kit that are specific for the detection of different carbapenemase genes.
Table 1 : DNA primer pairs included in the kit that are specific for the detection of different carbapenemase genes
Figure imgf000007_0001
Figure imgf000008_0001
Figure imgf000009_0001
20
The content of these kits contains a solution and materials called master mix, which includes Taq DNA polymerase enzyme and primers specific to the region to be amplified, as well as tubes prepared as control. With the PCR kit selected according to the suspected resistance enzyme, the reaction is completed in a short time (approximately 3-4 hours) in a thermal cycling device. For the final step, DNA sequence and variant analysis (10), PCR samples are run on a 1% agarose gel at 100V for 30 minutes if the traditional PCR kit is selected. If a Real-Time PCR kit is selected, Melt-Curve analysis and accurate melting points as well as internal amplification controls (IAK) are evaluated, and results are recorded. The enzyme variation will also be statistically evaluated by examining the nucleotide differences according to the DNA Sequence Analysis result of the selected samples.

Claims

CLAIMS PCR-based diagnostic kit for detection of antibiotic-resistant carbapenemase, characterized in that it comprises DNA primer pairs NO:1, NO:2 and NO:3, NO:4, NO:5, NO:6, NO:7, NO:8, NO:9, NO: 10, NO: 11, NO: 12, NO: 13, NO: 14, NO: 15, NO: 16, NO: 17, NO: 18, NO: 19, NO:20, NO:21, NO:22, NO:23, NO:24, NO:25, NO:26, NO:27, NO:28, NO:29, NO:30 including Klebsiella pneumoniae carbapenemase (KPC) belonging to the carbapenemase group, New Delhi metallo-P-lactamase (NDM), oxacillinase-48 (Oxa-48), Colistin Resistance (MCR), Oxacillinase-23 (Oxa-23), Oxacillinase-24 (Oxa- 24), Oxacillinase-58 (Oxa-58), Pseudomonas aeruginosa carbapenemases (blaVIM, blaTMP, and blaBIC), enterococcal Vancomycin resistance genes (vanA, vanB), Staphylococcus aureus methicillin resistance gene (MecA) to detect enzyme types from the carbapenemase group, and as Internal Controls Klebsiella pneumoniae 16S-rRNA Internal Control KPIC and Acinetobacter baumannii 16S-rRNA (ABIC). The method of operation of the PCR-based diagnostic kit according to claim 1, characterized in that it comprises the following process steps;
• producing bacteria (1) such as carbapenemase-positive Escherichia coli and Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus fecalis, Staphylococcus aureus by accumulation at -80 °C,
• obtaining bacterial cultures (3) from clinical samples (2), such as blood, endotracheal aspirate, or sputum,
• direct DNA isolation from clinical specimens (4) and DNA isolation from bacterial culture (5),
• standardization of DNA isolation, determination of specificity and susceptibility (6),
• producing kits for enzyme detection by Conventional Single (7) or Multiplex (8) and Multiplex Sybr-Green (9), Probe-Hybridization (10) techniques,
• DNA sequence and variant analysis (11).
8
PCT/TR2022/051394 2021-12-04 2022-12-01 Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit WO2023107058A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22904821.0A EP4413152A2 (en) 2021-12-04 2022-12-01 Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021/019090 2021-12-04
TR2021019090 2021-12-04

Publications (2)

Publication Number Publication Date
WO2023107058A2 true WO2023107058A2 (en) 2023-06-15
WO2023107058A3 WO2023107058A3 (en) 2023-08-03

Family

ID=86731435

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/051394 WO2023107058A2 (en) 2021-12-04 2022-12-01 Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit

Country Status (1)

Country Link
WO (1) WO2023107058A2 (en)

Also Published As

Publication number Publication date
WO2023107058A3 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
JP6258360B2 (en) Methods and kits for detecting antibiotic-resistant bacteria
AU2008242250B2 (en) Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria
Kommedal et al. Direct 16S rRNA gene sequencing from clinical specimens, with special focus on polybacterial samples and interpretation of mixed DNA chromatograms
Zhang et al. Evaluation of a micro/nanofluidic chip platform for the high-throughput detection of bacteria and their antibiotic resistance genes in post-neurosurgical meningitis
Stefaniuk et al. Evaluation of the BD Phoenix automated identification and susceptibility testing system in clinical microbiology laboratory practice
Mencacci et al. Comparison of conventional culture with SeptiFast real-time PCR for microbial pathogen detection in clinical specimens other than blood
WO2018074762A1 (en) Quantamatrix assay platform-based diagnostic method and kit capable of detecting and identifying gram-positive and gram-negative bacteria and candida species and determining resistance to antibiotics simultaneously
Barraud et al. Shotgun metagenomics for microbiome and resistome detection in septic patients with urinary tract infection
CN110669851A (en) Primer and/or probe composition for detecting cocci causing bloodstream infections and use thereof
CN111593131A (en) Primer probe system and kit capable of simultaneously detecting multiple drug-resistant genes
Wong et al. Disruption of adeB gene has a greater effect on resistance to meropenems than adeA gene in Acinetobacter spp. isolated from University Malaya Medical Centre.
Deutch et al. Diagnosis of ventricular drainage-related bacterial meningitis by broad-range real-time polymerase chain reaction
CN113584191B (en) Primer, probe and kit for multiplex PCR detection of 7 drug-resistant genes
CN110656188A (en) Primer and/or probe composition for detecting bacillus causing bloodstream infection and application thereof
EP2614155A1 (en) Method for detecting the presence of bacterial strains resistant to antibiotics in a biological sample
Shaker et al. Evaluation of combined use of temocillin disk and mastdisks inhibitor combination set against polymerase chain reaction for detection of carbapenem-resistant Enterobacteriaceae
Zalas-Więcek et al. Rapid detection of genes encoding extended-spectrum beta-lactamase and carbapenemase in clinical Escherichia coli isolates with eazyplex SuperBug CRE system
WO2023107058A2 (en) Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit
EP4413152A2 (en) Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit
Marbjerg et al. Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites: diagnostic value and implications for antimicrobial treatment
Rajni et al. Report on carbapenemase-producing rare sequence types of Escherichia coli and Enterobacter hormaechei
US20220145358A1 (en) Direct carbapenemase triple (kpc-2, oxa-48, ndm-1) pcr diagnostic kit
Mohamed et al. Phylogenetic Analysis of Klebsiella pneumoniae Isolated from Nosocomial and Community Infection in Diyala, Iraq
Huletsky et al. Bacterial genotypic drug resistance assays
Nordmann et al. Development of rapid diagnostic tests and screening culture media by the NARA for detection of multidrug resistance

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2022904821

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022904821

Country of ref document: EP

Effective date: 20240509

NENP Non-entry into the national phase

Ref country code: DE